This is a transformative event for Celcuity — its first approved product with compelling Phase 3 data. Monitor commercial launch execution in late Q3 2026 and sNDA submission for the PIK3CA-mutated cohort. The VIKTORIA-2 first-line trial results will be the next major catalyst.
Price Chart
Executive Summary
Celcuity announced FDA approval of REVTORPYK (gedatolisib) for HR+/HER2- locally advanced or metastatic breast cancer without a PIK3CA mutation, based on Phase 3 VIKTORIA-1 data showing a 76% reduction in risk of progression or death. This is the company's first approved product, transforming it from a clinical-stage biotech to a commercial-stage company, with launch expected in late Q3 2026.
Key Facts
- FDA approved REVTORPYK (gedatolisib) for HR+/HER2- locally advanced or metastatic breast cancer without PIK3CA mutation
- First and only FDA-approved therapy inhibiting all class I PI3K isoforms and mTORC1/2
- Phase 3 VIKTORIA-1: REVTORPYK triplet reduced risk of progression or death by 76% (HR=0.24) vs fulvestrant
- Median PFS: 9.3 months (triplet) vs 2.0 months (fulvestrant); ORR 32% vs 1%
- Commercial launch anticipated in late Q3 2026
- sNDA for PIK3CA-mutated cohort to be submitted in Q3 2026
- Ongoing Phase 3 VIKTORIA-2 trial in first-line advanced breast cancer
Financial Impact
First FDA approval transforms Celcuity from clinical-stage to commercial-stage; market cap $5.1B; no revenue or pricing disclosed
Risk Factors
- Commercial execution risk for a first-time launch
- Safety profile includes stomatitis (72%), rash, and hyperglycemia requiring monitoring
- Competition from existing PI3K/AKT/mTOR inhibitors and CDK4/6 combinations
- Dependence on single product for near-term revenue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3327323 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 26, 2026 5w ago | 8-K | $95.08 $84.00 | ▼ −11.65% | ▼ −12.86% | $72.51 (−23.74%) |
Jul 15, 2026 11w ago | 144 | $91.51 $92.08 | ▼ −0.62% | ▲ +1.72% | $72.51 (+20.76%) |
Jul 14, 2026 11w ago | Press Release | $91.51 $92.08 | ▲ +0.62% | ▼ −1.72% | $72.51 (−20.76%) |
Jun 11, 2026 16w ago | Institutional Cluster | $89.49 $113.51 | ▲ +26.84% | ▲ +24.95% | $72.51 (−18.97%) |
Jun 8, 2026 16w ago | 8-K | $92.59 $115.72 | ▲ +24.98% | ▲ +23.53% | $72.51 (−21.69%) |
Jun 5, 2026 17w ago | 424B5 | $88.28 $108.58 | ▲ +23.00% | ▲ +21.13% | $72.51 (−17.86%) |
Jun 4, 2026 17w ago | Press Release | $92.47 $107.95 | ▲ +16.74% | ▲ +18.11% | $72.51 (−21.59%) |
Jun 3, 2026 17w ago | Press Release | $88.95 $107.95 | ▼ −21.36% | ▼ −22.36% | $72.51 (+18.48%) |
Jun 3, 2026 17w ago | 424B5 | $88.95 $107.95 | ▼ −21.36% | ▼ −22.36% | $72.51 (+18.48%) |
Jun 2, 2026 17w ago | 8-K | $91.42 $104.49 | ▲ +14.30% | ▲ +15.86% | $72.51 (−20.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access